Review Article: Second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults

Abstract

Objective. To review the pharmacology, pharmacokinetics, efficacy, and safety of two new thrombopoietic (TPO) receptor agonists, romiplostim and eltrombopag, in the treatment of chronic idiopathic thrombocytopenic purpura (ITP) in adults.

Data sources. A MEDLINE search was conducted (1966 to March 2009) using the search terms romiplostim, AMG 531, eltrombopag, SB-497115, idiopathic thrombocytopenic purpura. Articles on phases 1—3 clinical trials in patients with ITP were identified and reviewed. References from manufacturer information, and abstracts from recent hematology meetings, were also evaluated.

Study selection and data extraction. Controlled clinical trials evaluating romiplostim and eltrombopag for treatment of chronic ITP in adults were selected from the data sources. All published relevant abstracts were also included.

Data synthesis. Limited randomized controlled trials and open-label ongoing long-term extension studies for romiplostim and eltrombopag, have shown that both TPO agonists are effective in improving the platelet count and reducing the bleeding episodes in adult patients with ITP unresponsive to at least one standard treatment. The most common adverse events associated with the drugs are mild to moderate headaches. The use of these agents has also been associated with rare but serious side-effects including bone marrow reticulin fibrosis, thrombotic events, and myeloid malignancies.

Conclusions. Until more long-term follow-up data regarding the safety, as well as comparative studies that further define the role of TPO agonists versus other agents in the treatment of chronic ITP are available, these agents should be reserved for patients with ITP refractory or intolerant to standard therapy. J Oncol Pharm Practice (2010) 16: 89—103.

Keywords

romiplostim AMG 531 eltrombopag SB-497115 idiopathic thrombocytopenic purpura

Get full access to this article

View all access options for this article.

References

Cines DB , Blanchette VS Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.

Stasi R. , Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79: 504-22.

Stasi R. , Evangelista ML , Stipa E. , Buccisano F. , Venditti A. , Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99: 4-13.

Gernsheimer TB The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2008; 219-26.

Segal JB , Powe NR Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4: 2377-83.

George JN , Woolf SH , Raskob GE , Wasser JS , Aledort LM , Ballem PJ et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.

British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-96.

Stasi R. , Stipa E. , Masi M. , Cecconi M. , Scimò MT , Oliva F. et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-42.

Godeau B. , Chevret S. , Varet B. , Lefrére F. , Zini JM , Bassompierre F. et al. Intravenous immunoglobulin or high-dose methylprednisolone. with or without oral prednisone. for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised. multicentre trial. Lancet 2002; 359: 23-29.

10.

Li J. , Yang C. , Xia Y. , Bertino A. , Glaspy J. , Roberts M. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin . Blood 2001; 98: 3241-48.

11.

Product information. Nplate (romiplostim) . California: Amgen, August 2008.

12.

Product information. Promacta (elotrombopag) . North Carolina: GlaxoSmithKline , October 2008.

13.

Wang B. , Nichol JL , Sullivan JT Pharmacodynamics and pharmacokinetics of AMG 531. a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76: 628-38.

14.

Broudy VC , Lin NL AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25: 52-60.

15.

Erhardt J. , Erickson-Miller CL , Tapley P. SB 497115-GR. a low molecular weight TPOR agonist. does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood 2004; 104: abstract 3888.

16.

Psaila B. , Bussel JB , Linden MD , Li YF , Barnard MR , Tate CM et al. In vivo effects of eltrombopag on human platelet function. Blood 2007; 110: abstract 1301.

17.

Stasi R. , Evangelista ML , Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68: 901-12.

18.

Yokoyama S. , Ikeda H. , Haramaki N. , Yasukawa H. , Murohara T. , Imaizumi T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates . J Am Coll Cardiol 2005; 45: 1280-86.

19.

Jenkins JM , Williams D. , Deng Y. , Uhl J. , Kitchen V. , Collins D. et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739-41.

20.

Newland A. , Caulier MT , Kappers-Klunne M. , Schipperus MR , Lefrere F. , Zwaginga JJ et al. An open-label. unit dose-finding study of AMG 531. a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135: 547-53.

21.

Kumagai Y. , Fujita T. , Ozaki M. , Sahashi K. , Ohkura M. , Ohtsu T. et al. Pharmacodynamics and pharmacokinetics of AMG 531. a thrombopoiesis-stimulating peptibody. in healthy Japanese subjects: a randomized. placebo-controlled study. J Clin Pharmacol 2007; 47: 1489-97.

22.

Bussel JB , Kuter DJ , George JN , McMillan R. , Aledort LM , Conklin GT et al. AMG 531. a thrombopoiesis-stimulating protein. for chronic ITP . N Engl J Med 2006; 355: 1672-81.

23.

Kuter DJ , Bussel JB , Lyons RM , Pullarkat V. , Gernsheimer TB , Senecal FM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371: 395-403.

24.

Bussel JB , Kuter DJ , Pullarkat V. , Lyons RM , Guo M. , Nichol JL Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-71.

25.

Tarantino M. , Sunkara U. , George J. , Aledort LM , Guo M. , Berger D. et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenic purpura. Blood 2008; 112: abstract 3422.

26.

Bussel JB , Cheng G. , Saleh MN , Psaila B. , Kovaleva L. , Meddeb B. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-47.

27.

Cheng G. , Saleh MN , Bussel JB , Marcher C. , Vasey S. , Mayer B. et al. Oral Eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double-blind, placebo-controlled study (RAISE). Blood 2008 ; 112: abstract 400.

28.

Bussel JB , Cheng G. , Kovaleva L. , Saleh MN , Balkis Meddeb B. , Mayer B. et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): Preliminary data from the EXTEND study. Blood 2007; 110: abstract 566.

29.

Cheng G. , Bussel JB , Saleh MN , Meddeb B. , De Obaldia ME , Aivado M. et al. Eltrombopag delivers clinical benefit in chronic idiopathic thrombocytopenic Purpura (ITP) patients not achieving platelet counts ≥50. 000 µL - data from the EXTEND study. Blood 2008; 112: abstract 3430.

30.

Liebman H. , Henry D. , Lefrere F. , Viallard JF , Lichtin A. , George J. et al. Long-term safety profile of romiplostim in patients with chronic immune thrombocytopenia (ITP). Blood 2008; 112: abstract 3415.

31.

Kantarjian H. , Fenaux P. , Sekeres MA , Becker P. , Boruchov A. , Bowen D. et al. Phase 1 to 2 study of AMG-531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): Update including extended treatment. Blood 2007; 110: abstract 250.

32.

McHutchison JG , Dusheiko G. , Shiffman ML , Rodriguez-Torres M. , Sigal S. , Bourliere M. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36.